دورية أكاديمية
أعرض في EDS

Prediction of Pathologic Complete Response in Breast Cancer Patients Comparing Magnetic Resonance Imaging with Ultrasound in Neoadjuvant Setting.

التفاصيل البيبلوغرافية
العنوان: Prediction of Pathologic Complete Response in Breast Cancer Patients Comparing Magnetic Resonance Imaging with Ultrasound in Neoadjuvant Setting.
المؤلفون: Palshof FK; University of Copenhagen, Copenhagen, Denmark. frederik.knude.palshof.01@regionh.dk., Lanng C; Department of Breast Surgery, Rigshospitalet/Herlev-Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark., Kroman N; Department of Breast Surgery, Rigshospitalet/Herlev-Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark., Benian C; Department of Radiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Vejborg I; Department of Radiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Bak A; Department of Radiology, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark., Talman ML; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Balslev E; Department of Pathology, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark., Tvedskov TF; Department of Breast Surgery, Rigshospitalet/Herlev-Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
المصدر: Annals of surgical oncology [Ann Surg Oncol] 2021 Nov; Vol. 28 (12), pp. 7421-7429. Date of Electronic Publication: 2021 May 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2005- : New York, NY : Springer
Original Publication: New York, NY : Raven Press, c1994-
مواضيع طبية MeSH: Breast Neoplasms*/diagnostic imaging , Breast Neoplasms*/drug therapy , Neoadjuvant Therapy*, Chemotherapy, Adjuvant ; Female ; Humans ; Magnetic Resonance Imaging ; Retrospective Studies ; Treatment Outcome ; Ultrasonography
مستخلص: Background: Some subgroups of breast cancer patients receiving neoadjuvant chemotherapy (NACT) show high rates of pathologic complete response (pCR) in the breast, proposing the possibility of omitting surgery. Prediction of pCR is dependent on accurate imaging methods. This study investigated whether magnetic resonance imaging (MRI) is better than ultrasound (US) in predicting pCR in breast cancer patients receiving NACT.
Methods: This institutional, retrospective study enrolled breast cancer patients receiving NACT who were examined by either MRI or combined US and mammography before surgery from 2016 to 2019. Imaging findings were compared with pathologic response evaluation of the tumor. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy for prediction of pCR were calculated and compared between MRI and US.
Results: Among 307 patients, 151 were examined by MRI and 156 by US. In the MRI group, 37 patients (24.5 %) had a pCR compared with 51 patients (32.7 %) in the US group. Radiologic complete response (rCR) was found in 35 patients (23.2 %) in the MRI group and 26 patients (16.7 %) in the US group. In the MRI and US groups, estimates were calculated respectively for sensitivity (87.7 % vs 91.4 %), specificity (56.8 % vs 33.3 %), PPV (86.2 % vs 73.8 %), NPV (60.0 % vs 65.4 %), and accuracy (80.1 % vs 72.4 %).
Conclusions: In predicting pCR, MRI was more specific than US, but not sufficiently specific enough to be a valid predictor of pCR for omission of surgery. As an imaging method, MRI should be preferred when future studies investigating prediction of pCR in NACT patients are planned.
(© 2021. Society of Surgical Oncology.)
References: Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85. https://doi.org/10.1200/jco.1998.16.8.2672 . (PMID: 10.1200/jco.1998.16.8.26729704717)
Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast-conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994;30:645–52. https://doi.org/10.1016/0959-8049(94)90537-1 . (PMID: 10.1016/0959-8049(94)90537-1)
Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;2001(30):96–102. https://doi.org/10.1093/oxfordjournals.jncimonographs.a003469 . (PMID: 10.1093/oxfordjournals.jncimonographs.a003469)
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85. https://doi.org/10.1200/jco.2007.15.0235 . (PMID: 10.1200/jco.2007.15.023518258986)
Chen M, Zhan WW, Han BS, et al. Accuracy of physical examination, ultrasonography, and magnetic resonance imaging in predicting response to neo-adjuvant chemotherapy for breast cancer. Chin Med J. 2012;125:1862–6. (PMID: 22884043)
Hayashi N, Tsunoda H, Namura M, et al. Magnetic resonance imaging combined with second-look ultrasonography in predicting pathologic complete response after neoadjuvant chemotherapy in primary breast cancer patients. Clin Breast Cancer. 2019;19:71–7. https://doi.org/10.1016/j.clbc.2018.08.004 . (PMID: 10.1016/j.clbc.2018.08.00430206035)
Bouzon A, Iglesias A, Acea B, Mosquera C, Santiago P, Mosquera J. Evaluation of MRI accuracy after primary systemic therapy in breast cancer patients considering tumor biology: optimizing the surgical planning. Radiol Oncol. 2019;53:171–7. https://doi.org/10.2478/raon-2019-0023 . (PMID: 10.2478/raon-2019-0023311040016572491)
Fukuda T, Horii R, Gomi N, et al. Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype. Springerplus. 2016;5:152. https://doi.org/10.1186/s40064-016-1800-x . (PMID: 10.1186/s40064-016-1800-x270268494766139)
Namura M, Tsunoda H, Yagata H, et al. Discrepancies between pathological tumor responses and estimations of complete response by magnetic resonance imaging after neoadjuvant chemotherapy differ by breast cancer subtype. Clin Breast Cancer. 2018;18:128–34. https://doi.org/10.1016/j.clbc.2017.07.001 . (PMID: 10.1016/j.clbc.2017.07.00128843513)
Houssami N, MacAskill P, Von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012. https://doi.org/10.1016/j.ejca.2012.05.023 . (PMID: 10.1016/j.ejca.2012.05.02322766518)
van la Parra RF, Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res. 2016;18:28. https://doi.org/10.1186/s13058-016-0684-6 . (PMID: 10.1186/s13058-016-0684-6)
Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017. https://doi.org/10.1093/annonc/mdx308 .
van der Noordaa MEM, van Duijnhoven FH, Loo CE, et al. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment). Breast. 2018;40:76–81. https://doi.org/10.1016/j.breast.2018.04.015 . (PMID: 10.1016/j.breast.2018.04.01529698928)
Kuerer HM, Rauch GM, Krishnamurthy S, et al. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy. Ann Surg. 2018;267:946–51. https://doi.org/10.1097/sla.0000000000002313 . (PMID: 10.1097/sla.000000000000231328549010)
Schaefgen B, Mati M, Sinn HP, et al. Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response? Ann Surg Oncol. 2016;23:789–95. https://doi.org/10.1245/s10434-015-4918-0 . (PMID: 10.1245/s10434-015-4918-026467456)
Shin HJ, Kim HH, Ahn JH, et al. Comparison of mammography, sonography, MRI, and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. Br J Radiol. 2011;84:612–20. https://doi.org/10.1259/bjr/74430952 . (PMID: 10.1259/bjr/74430952210815793473500)
Marinovich ML, Macaskill P, Irwig L, et al. Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. Br J Cancer. 2013;109:1528–36. https://doi.org/10.1038/bjc.2013.473 . (PMID: 10.1038/bjc.2013.473239631403776985)
Vriens BE, de Vries B, Lobbes MB, et al. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer. Eur J Cancer. 2016;52:67–76. https://doi.org/10.1016/j.ejca.2015.10.010 . (PMID: 10.1016/j.ejca.2015.10.01026650831)
Taydas O, Durhan G, Akpinar MG, Demirkazik FB. Comparison of MRI and US in tumor size evaluation of breast cancer patients receiving neoadjuvant chemotherapy. Eur J Breast Heal. 2019;15:119–24. https://doi.org/10.5152/ejbh.2019.4547 . (PMID: 10.5152/ejbh.2019.4547)
Park J, Chae EY, Cha JH, et al. Comparison of mammography, digital breast tomosynthesis, automated breast ultrasound, magnetic resonance imaging in evaluation of residual tumor after neoadjuvant chemotherapy. Eur J Radiol. 2018;108:261–8. https://doi.org/10.1016/j.ejrad.2018.09.032 . (PMID: 10.1016/j.ejrad.2018.09.03230396666)
Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography, and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004;14:1371–9. https://doi.org/10.1007/s00330-004-2246-z . (PMID: 10.1007/s00330-004-2246-z14986052)
Danish Breast Cancer Cooperative Group. Pathology Guidelines. DBCG. Published 2013. Retrieved 17 July 2020 at https://www.dmcg.dk/siteassets/forside/kliniske-retningslinjer/godkendte-kr/dbcg/dbcg_patologiprocedure_rkkp_admgodk300420x.pdf .
Müller HD, Posch F, Suppan C, et al. Validation of residual cancer burden as prognostic factor for breast cancer patients after neoadjuvant therapy. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07741-w . (PMID: 10.1245/s10434-019-07741-w314520526864028)
Campbell JI, Yau C, Krass P, et al. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017. https://doi.org/10.1007/s10549-017-4303-8 . (PMID: 10.1007/s10549-017-4303-8292800435843537)
Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005. https://doi.org/10.1200/JCO.2005.07.032 . (PMID: 10.1200/JCO.2005.07.03216361629)
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER. Lancet. 2010. https://doi.org/10.1016/S0140-6736(09)61964-4 . (PMID: 10.1016/S0140-6736(09)61964-420113825)
van Ramshorst MS, Loo CE, Groen EJ, et al. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2017. https://doi.org/10.1007/s10549-017-4254-0 . (PMID: 10.1007/s10549-017-4254-028432515)
Gampenrieder SP, Peer A, Weismann C, et al. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). Breast Cancer Res. 2019. https://doi.org/10.1186/s13058-018-1091-y . (PMID: 10.1186/s13058-018-1091-y307044936357474)
Baumgartner A, Tausch C, Hosch S, et al. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast. 2018. https://doi.org/10.1016/j.breast.2018.02.028 . (PMID: 10.1016/j.breast.2018.02.02829518677)
De Los Santos JF, Cantor A, Amos KD, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: translational Breast Cancer Research Consortium trial 017. Cancer. 2013. https://doi.org/10.1002/cncr.27995 . (PMID: 10.1002/cncr.2799523436342)
Weber JJ, Jochelson MS, Eaton A, et al. MRI and prediction of pathologic complete response in the breast and axilla after neoadjuvant chemotherapy for breast cancer. J Am Coll Surg. 2017. https://doi.org/10.1016/j.jamcollsurg.2017.08.027 . (PMID: 10.1016/j.jamcollsurg.2017.08.027289195795705460)
Zhang K, Li J, Zhu Q, Chang C. Prediction of pathologic complete response by ultrasonography and magnetic resonance imaging after neoadjuvant chemotherapy in patients with breast cancer. Cancer Manage Res. 2020;12:2603–12. https://doi.org/10.2147/CMAR.S247279 . (PMID: 10.2147/CMAR.S247279)
Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol. 2011;18:3160–3. https://doi.org/10.1245/s10434-011-1919-5 . (PMID: 10.1245/s10434-011-1919-521947594)
Bouzon A, Acea B, Soler R, et al. Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients. Radiol Oncol. 2016;50:73–9. https://doi.org/10.1515/raon-2016-0007 . (PMID: 10.1515/raon-2016-0007270694524825338)
Heil J, Schaefgen B, Sinn P, et al. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy? Eur J Cancer. 2016. https://doi.org/10.1016/j.ejca.2016.09.034 . (PMID: 10.1016/j.ejca.2016.09.03427821317)
Basik M, Costantino JP, De Los Santos JF, et al. NRG Oncology BR005: phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility. J Clin Oncol. 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps604 . (PMID: 10.1200/jco.2018.36.15_suppl.tps604)
Heil J, Sinn P, Richter H, et al. RESPONDER: diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer: a multicenter, confirmative, one-armed, intra-individually controlled, open, diagnostic trial. BMC Cancer. 2018. https://doi.org/10.1186/s12885-018-4760-4 . (PMID: 10.1186/s12885-018-4760-4301448186109284)
Lee H-B, Han W, Kim S-Y, et al. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial. Breast Cancer Res Treat. 2020;182:97–105. https://doi.org/10.1007/s10549-020-05678-3 . (PMID: 10.1007/s10549-020-05678-332418044)
تواريخ الأحداث: Date Created: 20210527 Date Completed: 20211020 Latest Revision: 20211209
رمز التحديث: 20221213
DOI: 10.1245/s10434-021-10117-8
PMID: 34043094
قاعدة البيانات: MEDLINE
الوصف
تدمد:1534-4681
DOI:10.1245/s10434-021-10117-8